EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Newron Pharmaceuticals SpA's Enterprise Value is $329.38 Mil.
Newron Pharmaceuticals SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $37.24 Mil. Therefore, Newron Pharmaceuticals SpA's EV-to-FCF for today is 8.85.
The historical rank and industry rank for Newron Pharmaceuticals SpA's EV-to-FCF or its related term are showing as below:
NWPHF'
s EV-to-FCF Range Over the Past 10 Years
Min: -31.87 Med: -6.91 Max: 20.42
Current: 8.96
During the past 13 years, the highest EV-to-FCF of Newron Pharmaceuticals SpA was 20.42. The lowest was -31.87. And the median was -6.91.
NWPHF's EV-to-FCF is ranked better than 61.26% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs NWPHF: 8.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Newron Pharmaceuticals SpA's PE Ratio (TTM) for today is calculated as:
Newron Pharmaceuticals SpA's share price for today is $20.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.773.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Newron Pharmaceuticals SpA EV-to-FCF Related Terms
Newron Pharmaceuticals SpA EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Newron Pharmaceuticals SpA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newron Pharmaceuticals SpA EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Newron Pharmaceuticals SpA's EV-to-FCF falls into.
Newron Pharmaceuticals SpA's current Enterprise Value is $329.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Newron Pharmaceuticals SpA's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $37.24 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newron Pharmaceuticals SpA (NWPHF) has a EV-to-FCF of 8.85 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Newron Pharmaceuticals SpA and its competitors. According to the industry distribution chart, Newron Pharmaceuticals SpA ranks #129 out of 333 companies in the Biotechnology industry, placing it in the top 38.7%.
Is Newron Pharmaceuticals SpA's EV-to-FCF too high?
Newron Pharmaceuticals SpA's current EV-to-FCF is 8.85. The Biotechnology industry median EV-to-FCF is 15.57. Newron Pharmaceuticals SpA's value of 8.85 is 43.2% below this industry median. Based on the distribution chart, Newron Pharmaceuticals SpA ranks #129 out of 333 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Newron Pharmaceuticals SpA ranks #129 out of 333 companies for EV-to-FCF. This puts Newron Pharmaceuticals SpA in the upper half of its industry. The industry median EV-to-FCF is 15.57. Newron Pharmaceuticals SpA's value of 8.85 is 43.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newron Pharmaceuticals SpA's current EV-to-FCF of 8.85 is 43.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Newron Pharmaceuticals SpA and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newron Pharmaceuticals SpA's current EV-to-FCF is 8.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Newron Pharmaceuticals SpA (NWPHF) has a current EV-to-FCF of 8.85. The stock's GF Value™ is $20.44, compared to a current price of $20.00 — trading 2.2% below its estimated fair value. The current EV-to-FCF is 8.85 and 43.2% below the Biotechnology industry median of 15.57. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (NWPHF), the current EV-to-FCF is 8.85 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newron Pharmaceuticals SpA (NWPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued.
The current stock price of $20.00 is trading 2.2% below its estimated GF Value™ of $20.44.
Key valuation signals for NWPHF:
EV-to-FCF: 8.85
GF Value™: $20.44 vs. price of $20.00 (2.2% below fair value)
Industry Position: 43.2% below the Biotechnology median (#129 of 333)
No single metric tells the full story. See the NWPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score
Get the complete analysis for NWPHF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NWPHF has been successfully added to your 
